key: cord-0948147-vlys7q11 authors: Offerhaus, Joost A.; Wilde, Arthur A.M.; Remme, Carol Ann title: Prophylactic (hydroxy)chloroquine in COVID-19: potential relevance for cardiac arrhythmia risk date: 2020-07-03 journal: Heart Rhythm DOI: 10.1016/j.hrthm.2020.07.001 sha: dd7052c5de2bd413c069104e525144d90a885579 doc_id: 948147 cord_uid: vlys7q11 (Hydroxy)chloroquine ((H)CQ) is being investigated as treatment for COVID-19, but studies have so far demonstrated either no or a small benefit. However, these studies have been mostly performed in patients admitted to hospital and hence likely already (severely) affected. Another suggested approach employs prophylactic (H)CQ treatment aimed at preventing either SARS-CoV-2 infection or development of disease. A substantial number of clinical trials are planned or underway aimed at assessing the prophylactic benefit of (H)CQ. However, (H)CQ may lead to QT-prolongation and potentially induce life-threatening arrhythmias. This may be of particular relevance for patients with pre-existing cardiovascular disease and those taking other QT-prolonging drugs. In addition, it is known that a certain percentage of the population carries genetic variant(s) which reduces their repolarization reserve, predisposing them to (H)CQ-induced QT-prolongation, and this may be more relevant in females who already have a longer QT to start with. This review provides an overview of the current evidence on (H)CQ therapy in COVID-19 patients and discusses different strategies for prophylactic (H)CQ therapy (i.e. pre-infection, post-exposure, post-infection). In particular, the potential cardiac effects, including QT-prolongation and arrhythmias will be addressed. Based on these insights, recommendations will be presented as to which preventive measures should be taken when giving (H)CQ prophylactically, including ECG monitoring. Since December 2019, the SARS-CoV-2 virus has infected over 7 million people worldwide 27 as of June 8 th 2020 (https://coronavirus.jhu.edu/map.html) with some individuals (particularly 28 those of older age and/or with co-morbidities) developing COVID-19, a critical pulmonary 29 illness requiring intensive treatment. In addition, COVID-19 patients are at increased risk for without serious side-effects. 5 However, it is known that a certain percentage of the general 51 population carries genetic variant(s) which may predispose them to (H)CQ-induced pro-52 arrhythmia. We here explore the potential prophylactic use of (H)CQ in SARS-CoV-2 53 infection, the expected side-effects and toxicity in the population to be targeted, and the 54 recommended safety measures to prevent life-threatening arrhythmias. range) than that reported in healthy volunteers (±400 ms) (Fig. 1) . 27 approach, enlisting a cumulative estimated sample size of 175,000 individuals (Fig. 2) . Of 170 these, 36 (sub)studies start therapy in pre-exposed-, 13 in confirmed post-exposed-and 17 in have been published. One small non-randomized, non-controlled study administered HCQ in 9 211 SARS-CoV-2 negative individuals, who were all exposed to one index patient, and found 176 that none of these cases had a positive PCR test after 14 days of quarantine. 35 However, this 177 study is severely limited by the lack of a control group and the fact that almost none of the 178 exposed individuals fell in the high-risk exposure group. More recently, the first randomized 179 controlled trial testing (H)CQ as prophylaxis has been published. 36 In this study, 821 post-180 exposed individuals, who were recruited via social media, were treated with HCQ or placebo 181 within 4 days of exposure. The incidence of developing COVID-19, which was defined 182 through clinical evaluation in the vast majority of cases (~80%) due to a limited access to 183 diagnostic tests, was relatively low and not different between the groups (i.e. 12-14%). However, the study was limited by the fact that PCR diagnosis was not performed in most 185 participants, and follow-up data collection was through self-reporting. Overall, the study 186 design may not have been optimal to identify a beneficial, preventive effect of HCQ in mildly 187 affected patients. In addition, whether (H)CQ is effective in pre-exposed individuals remains 188 unknown, and it will be interesting to see the results of other ongoing RCTs on this topic. Current perspectives on Coronavirus 2019 316 (COVID-19) and cardiovascular disease: A white paper by the JAHA editors Remdesivir for the Treatment of Covid-19 319 -Preliminary Report Hydroxychloroquine in patients with mainly mild to 322 moderate coronavirus disease 2019: open label, randomised controlled trial Cardiotoxicity of antimalarial drugs Heart conduction disorders 327 related to antimalarials toxicity: an analysis of electrocardiograms in 85 patients treated 328 with hydroxychloroquine for connective tissue diseases Mechanisms of action of hydroxychloroquine and 331 chloroquine: implications for rheumatology Remdesivir and chloroquine effectively inhibit the 334 recently emerged novel coronavirus (2019-nCoV) in vitro In vitro inhibition of severe 337 acute respiratory syndrome coronavirus by chloroquine Chloroquine is a potent inhibitor of SARS 340 coronavirus infection and spread Hydroxychloroquine, a less toxic derivative of chloroquine, 342 is effective in inhibiting SARS-CoV-2 infection in vitro Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory 346 SARS-CoV-2) Rethinking the role of 349 hydroxychloroquine in the treatment of COVID-19 Hydroxychloroquine and azithromycin as a 352 treatment of COVID-19: results of an open-label non-randomized clinical trial Breakthrough: Chloroquine phosphate has shown apparent 355 efficacy in treatment of COVID-19 associated pneumonia in clinical studies Efficacy of hydroxychloroquine in patients with COVID-358 19: results of a randomized clinical trial COVID-19 coronavirus research has 361 overall low methodological quality thus far: case in point for 362 chloroquine/hydroxychloroquine No evidence of clinical efficacy of 365 hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen 366 requirement: results of a study using routinely collected data to emulate a target trial Observational Study of Hydroxychloroquine in 369 Hospitalized Patients with Covid-19 Association of Treatment With 372 Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With 373 COVID-19 in Outcomes of hydroxychloroquine usage in 375 United States veterans hospitalized with Covid-19 Of chloroquine and COVID-19 Collation, assessment and analysis of literature in 380 vitro data on hERG receptor blocking potency for subsequent modeling of drugs' 381 cardiotoxic properties Chloroquine-induced QTc prolongation in COVID-19 patients Pointes in Patients with COVID-19 treated with Hydroxychloroquine/Azithromycin The risk for QTc interval 389 prolongation in COVID-19 patients treated with chloroquine Effect of High vs Low Doses of 392 Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe 393 Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized 394 Clinical Trial Randomized Dose-Ranging Controlled Trial of 397 AQ-13, a Candidate Antimalarial, and Chloroquine in Healthy Volunteers Determination and Interpretation of the QT 400 Interval Metabolic syndrome and its components as risk factors for prolonged 403 corrected QT interval in apparently healthy Korean men and women Spectrum of drugs prolonging QT interval and the incidence of torsades de 406 pointes Cardiac late 412 Na+ current: Proarrhythmic effects, roles in long QT syndromes, and pathological 413 21 relationship to CaMKII and oxidative stress QT prolongation, torsades de 416 pointes, and sudden death with short courses of chloroquine or hydroxychloroquine as 417 used in COVID-19: A systematic review. Heart Rhythm Chloroquine-induced 420 torsades de pointes in a patient with coronavirus disease 2019. Heart Rhythm Can post-exposure prophylaxis for COVID-19 be considered 423 as an outbreak response strategy in long-term care hospitals? Hydroxychloroquine as Postexposure Prophylaxis for Covid-19 Attributed to Chloroquine and Hydroxychloroquine: A Systematic Review of the 430 The arrhythmogenic cardiotoxicity of 432 the quinoline and structurally related antimalarial drugs: A systematic review Factors affecting the electrocardiographic QT 435 interval in malaria: A systematic review and meta-analysis of individual patient data Electrocardiogram 438 22 abnormalities related to anti-malarials in systemic lupus erythematosus Hydroxychloroquine and Azithromycin: An Analysis of the World Health Organization 442 Pharmacovigilance Database. Circulation Safety signals for QT prolongation or 446 Torsades de Pointes associated with azithromycin with or without chloroquine or 447 hydroxychloroquine Estimates of Population-Based Incidence of Malignant Arrhythmias 449 Associated with Medication Use -a Narrative Review The friendly use of chloroquine in the COVID-452 19 disease: A warning for the G6PD -deficient males and for the unaware carriers of 453 pathogenic alterations of the G6PD gene A Large Candidate Gene Survey Identifies the 456 KCNE1 D85N Polymorphism as a Possible Modulator of Drug-Induced Torsades de Genetic Susceptibility for 460 COVID-19-Associated Sudden Cardiac Death in African Americans COVID-19, Clinical Trials and QT-Prolonging Prophylactic Therapy Healthy Subjects: First, Do No Harm SARS-CoV-2, COVID-19 and inherited 466 arrhythmia syndromes. Heart Rhythm With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among 469 Hospitalized Patients Testing Positive for Coronavirus Disease